FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:645-646 March 3, 1994 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Giralt, S.

To the Editor: The prognosis of patients with a relapse of leukemia within the first year after allogeneic bone marrow transplantation is dismal. Giralt et al. (Sept. 9 issue)¹ described seven patients whose leukemia had relapsed after allogeneic bone marrow transplantation. All were treated with granulocyte colony-stimulating factor (filgrastim) to induce terminal differentiation of the leukemic clone, selectively stimulate donor hematopoietic cells, and enhance the graft-versus-leukemia reaction. Three of the seven patients had a complete response, with reestablishment of hematopoiesis of donor origin. We observed such a trend toward a lower relapse rate in patients treated with recombinant granulocyte-macrophage colony-stimulating . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.